EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The Food and Drug Administration’s Role in Dermatologic Drug Development

Felisa S Lewis, Kendall A Marcus

Dermatologic Clinics · 2022-07 · 40 (3) · 249-263

DOI: 10.1016/j.det.2022.02.001 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Dermatologic Clinics, 2022-07. Verfasst von Felisa S Lewis und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology and Dentistry, Office of Inflammation and Immunology, Office of New Drugs, Center for Drug Evaluation and Research, Food and …. Hauptthemen laut MEDLINE: Drug Approval, Drug Development. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The mission of the Food and Drug Administration (FDA) is to ensure the safety and effectiveness of dermatologic drugs, as authorized by the Federal Food, Drug, and Cosmetic Act (FD&CA). In this article, we discuss how the FDA's policies and practices have continued to evolve to incorporate scientific advances and to facilitate approval for dermatologic drugs in a timely manner for a broad spectrum of patients. We provide several examples to highlight areas where the Division of Dermatology and Dentistry found common ground with stakeholders to increase the therapeutic options for dermatologic patients, while still maintaining regulatory standards required for approval.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalDrug DevelopmentAllergensHumansPharmaceutical PreparationsUnited StatesUnited States Food and Drug Administration

Stichwörter der Autor:innen

DermatologyDrug developmentFood and Drug AdministrationInvestigational New DrugNew Drug Application

Substanzen

AllergensPharmaceutical Preparations

Autor:innen und Institutionen

  • Division of Dermatology and Dentistry, Office of Inflammation and Immunology, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, WO22, 10903 New Hampshire Avenue, Silver Spring,…

Zitieren

APA

Lewis, F. S., & Marcus, K. A. (2022). The Food and Drug Administration’s Role in Dermatologic Drug Development. Dermatologic Clinics, 40(3), 249-263. https://doi.org/10.1016/j.det.2022.02.001

Vancouver

Lewis FS, Marcus KA. The Food and Drug Administration’s Role in Dermatologic Drug Development. Dermatologic Clinics. 2022;40(3):249-263. doi:10.1016/j.det.2022.02.001

BibTeX
@article{Lewis2022,
  author = {Lewis, Felisa S and Marcus, Kendall A},
  title = {The Food and Drug Administration’s Role in Dermatologic Drug Development},
  journal = {Dermatologic Clinics},
  year = {2022},
  volume = {40},
  number = {3},
  pages = {249--263},
  doi = {10.1016/j.det.2022.02.001}
}
Kostenlos starten →